

Adult CIRB - Early Phase Emphasis Meeting Agenda

August 18, 2026

I Continuing Review

10397, Optimizing Antibody-Drug Conjugate Therapy through Molecular Analysis for Therapy Choice (ADC MATCH) (Version Date 07/10/26)

II Continuing Review

10706, A Phase 2 Window of Opportunity Trial of Neoadjuvant Agonistic Anti-CD40 Antibody CDX-1140 and Cemiplimab (REGN2810) in AJCC Stage III-IV Head and Neck Cancer Patients Prior to Surgery (Version Date 12/19/25)

III Continuing Review

10708, A Phase 2 Pilot Study of Mirdametinib in Relapsed Refractory Chronic Lymphocytic Leukemia (Version Date 09/09/25)

IV Continuing Review

S1320, A Randomized Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E/K Mutant Melanoma (Version Date 11/24/25)
